SINOLINK Securities is a listed securities company with high-quality asset, professional talent pool and outstanding innovation ability. Adhering to the mission of “make financial services more efficient and reliable", SINOLINK Securities is a comprehensive securities firm with business radiating across China, and has been classified as Class A securities firm for ten consecutive years, and evaluated as Class A in M&A financial advisory for many consecutive years. We provide diversified investment banking services for enterprise customers, including but not limited to equity financing and M&A financial advisory. We maintain a leading position for the amount of healthcare companies we served as IPO sponsor since 2017.
At Warburg Pincus, private equity is the firm’s only business. Established more than 50 years ago, Warburg Pincus has invested more than $94 billion in more than 940 companies in more than 40 countries around the world.
Warburg Pincus’ globally integrated, private partnership ensures that all of the firm’s resources are committed to the success of each portfolio company. Warburg Pincus has a long history of partnering with entrepreneurs in all stages of development across industries and geographies and helping them scale.
Datasite is a leading SaaS provider for the M&A industry, empowering dealmakers around the world with the tools they need to succeed across the entire deal lifecycle. Datasite facilitates close to 10,000 deals annually. Dealmakers in more than 170countries make their deals in Datasite, including 74 of the top 100 legal firms, all the top 20 global financial advisory firms, and half of the top 10 largest deals in the US in 2020. For more information, visit www. datasite.com
Established in 1989, OrbiMed is healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$14 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 400 private companies across a wide range of therapeutic categories and stages of development. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OrbiMed Asia manages three Asia-focused PE/VC funds, totaling over $1 billion. It has made investments in 40 companies.
Morningside Ventures is Morningside Group’s venture arm founded by the Chan Family of Hong Kong in 1986, focused on making early stage healthcare/life science investments cross border and across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc.
Morningside Ventures is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.
Cooley is a full service global law firm, having more than 1000 lawyers across 14 offices in Asia, Europe and the United States. For over 40 years, Cooley has played an instrumental role in the growth of many of the most sophisticated companies in the life sciences industry, such as Amgen and Genentech, and is counsel to more than 50% of the companies on the NASDAQ Biotechnology Index. We focus on corporate partnering, licensing, complex mergers, acquisitions and disposition transactions, local and cross-border intellectual property issues, regulatory counselling, capital markets, supply and distribution arrangements and other commercial transactions. Our experience representing life sciences companies and investors also gives us insight into financings of companies at all stages of development.
We have been advising on Greater China-related matters over three decades. We are continuing our global growth by launching the Beijing office in January 2018 and with the recent announcement of plans to launch in Hong Kong.
SHANGHAI（NANXIANG）PRECISION MEDICINE INDUSTRIAL PARK